摘要
目的:检测肾透析患者纤维蛋白单体聚合速率(FMPV)、纤维蛋白原(Fbg)、D-二聚体(D-D)和血浆因子Ⅷ相关抗原(vWFAg)变化,评价速避凝(Fraxiparine)抗凝治疗后高凝状态的改变和意义。方法:用纤维蛋白单体聚合功能动力学方法和酶联免疫吸附法(ELISA)测定健康人和肾透析患者透析前、后及抗凝治疗后的FMPV、Fbg、D-D及vWFAg。结果:患者透析前、后血浆FMPV、Fbg、D-D及vWFAg水平显著增高(P<0.05或P<0.01),且透析后较透析前更高(P<0.05),抗凝治疗后FMPV较治疗前显著降低(P<0.05),D-D和vWFAg较治疗前显著升高(P<0.05)。结论:急、慢性肾功衰患者透析前、后和抗凝治疗后采用FMPV、Fbg、D-D及vWFAg等指标进行监测有重要临床应用价值。
Objective： To study the changes of FMPV,D-D and vWFAg in patients with hemodialysis and to discuss the clinical significance of hypercngulability during fraxiparine therapy. Method： Fibrin Monad Polymerization Velocity （FMPV） were measured in uraernia with nephritis and health individual. D-D dimer and vWFAg were measured by ELISA. Results： The plasma levels of FMPV, Fbg and D-D were elevated significanctly in all patients. After antithrombesis therapy, FMPV in patients with nephritis reduced significantly. D-D dimer and vWFAg are raised signifycantly. Fbg concentration in patients raised significantly than the control. FMPV in patients with chronic renal failure raised significantly than the control too. After anticoagulative therapy, FMPV in patient with acute renal failue reduced significantly. D-D and vWFAg raised significantly. Conclusion： FMPV, D-D and vWFAg may be risk factors of hypercogulability and thrombosis.
出处
《微循环学杂志》
2005年第3期53-54,F0006,F0009,共4页
Chinese Journal of Microcirculation
